Biotech Company Successfully Lists on Nasdaq Exchange
2 reports, 1 independent
Updated 00:00
Still developing
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A clinical-stage biotechnology company successfully listed on Nasdaq on November 13, 2026. The initial public offering was priced at $17.00 per share, and shares closed at $28.50 on the first trading day, representing a 68% increase from the IPO price. This resulted in a market capitalization of approximately $1.69 billion.
From manilatimes.net
Why it matters
The listing marks a significant capital event for the biotechnology firm, which is advancing ultra-long-acting antibody medicines for chronic inflammatory diseases. The company's lead program, WIN378, is a monoclonal antibody targeting TSLP.
From manilatimes.net
Who's involved
- NasdaqThe American stock exchange where the company listed its shares.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Nasdaq
American fully electronic stock exchange
Related events
- Company Q783794 was listed on the Nasdaq stock exchange.
- Royal Bank of Canada raised its position in Bright Minds Biosciences Inc., a company trading on the Nasdaq exchange.
- Brand Engagement Network was listed on the Nasdaq exchange on November 12, 2026.
- Innoviz Technologies listed its stock on the Nasdaq exchange on November 4, 2026.
- BioNano Genomics traded on the Nasdaq stock exchange on July 9, 2026.